A partial lesion model of Parkinson's disease in mice - Characterization of a 6-OHDA-induced medial forebrain bundle lesion

Behavioural Brain Research

Volumn 284, Issue , 2015, Pages 196-206

  Boix, Jordi ^a   Padel, Thomas ^a   Paul, Gesine ^a,b  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

6 Hydroxydopamine; Behavioral test; Medial forebrain bundle; Mouse model; Parkinson's disease; Prediction model

Indexed keywords

OXIDOPAMINE; AMPHETAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; INTERLEUKIN 1 RECEPTOR; MEMBRANE PROTEIN; TIRAP PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIORAL TEST; CONTROLLED STUDY; CORRIDOR TEST; CYLINDER TEST; DENSITOMETRY; DOPAMINERGIC NERVE CELL; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; MOUSE; NEUROPROTECTION; NONHUMAN; OVERALL SURVIVAL; PARKINSON DISEASE; PRIORITY JOURNAL; ROTATION; ROTATION TEST; SENSORIMOTOR INTEGRATION; SIGNAL TRANSDUCTION; STEPPING TEST; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; SURVIVAL RATE; ANIMAL; AREA UNDER THE CURVE; C57BL MOUSE; DOSE RESPONSE; DRUG EFFECTS; MOTOR ACTIVITY; PARKINSONISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RECEIVER OPERATING CHARACTERISTIC; SEVERITY OF ILLNESS INDEX; TRANSGENIC MOUSE;

AMPHETAMINE; ANIMALS; AREA UNDER CURVE; DOPAMINE AGENTS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; IMMUNOHISTOCHEMISTRY; MEDIAL FOREBRAIN BUNDLE; MEMBRANE GLYCOPROTEINS; MICE, INBRED C57BL; MICE, TRANSGENIC; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSONIAN DISORDERS; RECEPTORS, INTERLEUKIN-1; ROC CURVE; ROTATION; SEVERITY OF ILLNESS INDEX;

EID: 84923319244     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2015.01.053     Document Type: Article

References (49)

1. de Rijk M.C., Tzourio C., Breteler M.M., Dartigues J.F., Amaducci L., Lopez-Pousa S., et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. J Neurol Neurosurg Psychiatry 1997, 62:10-15.
2. Fearnley J.M., Lees A.J. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain: J Neurol 1991, 114(Pt 5):2283-2301.
3. Ehringer H., Hornykiewicz O. Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klinische Wochenschrift 1960, 38:1236-1239.
4. Blandini F., Armentero M.T. Animal models of Parkinson's disease. FEBS J 2012, 279:1156-1166.
5. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 2000, 39:777-787.
6. Ungerstedt U., Arbuthnott G.W. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 1970, 24:485-493.
7. Olsson M., Nikkhah G., Bentlage C., Bjorklund A. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci: Off J Soc Neurosci 1995, 15:3863-3875.
8. Dowd E., Monville C., Torres E.M., Dunnett S.B. The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 2005, 68:24-30.
9. Brundin P., Isacson O., Gage F.H., Prochiantz A., Bjorklund A. The rotating 6-hydroxydopamine-lesioned mouse as a model for assessing functional effects of neuronal grafting. Brain Res 1986, 366:346-349.
10. Mandel R.J., Randall P.K. Quantification of lesion-induced dopaminergic supersensitivity using the rotational model in the mouse. Brain Res 1985, 330:358-363.
11. Bensadoun J.C., Deglon N., Tseng J.L., Ridet J.L., Zurn A.D., Aebischer P. Lentiviral vectors as a gene delivery system in the mouse midbrain: cellular and behavioral improvements in a 6-OHDA model of Parkinson's disease using GDNF. Exp Neurol 2000, 164:15-24.
12. Parish C.L., Finkelstein D.I., Drago J., Borrelli E., Horne M.K. The role of dopamine receptors in regulating the size of axonal arbors. J Neurosci: Off J Soc Neurosci 2001, 21:5147-5157.
13. Grealish S., Mattsson B., Draxler P., Bjorklund A. Characterisation of behavioural and neurodegenerative changes induced by intranigral 6-hydroxydopamine lesions in a mouse model of Parkinson's disease. Eur J Neurosci 2010, 31:2266-2278.
14. Cenci M.A., Lundblad M. Ratings of L-DOPA-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice. Current protocols in neuroscience/Editorial Board 2007, Chapter 9: Unit 9.25. J.N. Crawley (Ed.).
15. Lundblad M., Picconi B., Lindgren H., Cenci M.A. A model of L-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis 2004, 16:110-123.
16. Heuer A., Smith G.A., Lelos M.J., Lane E.L., Dunnett S.B. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites. Behav Brain Res 2012, 228:30-43.
17. Francardo V., Recchia A., Popovic N., Andersson D., Nissbrandt H., Cenci M.A. Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to l-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease. Neurobiol Dis 2011, 42:327-340.
18. Iancu R., Mohapel P., Brundin P., Paul G. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice. Behav Brain Res 2005, 162:1-10.
19. Heuer A., Smith G.A., Dunnett S.B. Comparison of 6-hydroxydopamine lesions of the substantia nigra and the medial forebrain bundle on a lateralised choice reaction time task in mice. Eur J Neurosci 2013, 37:294-302.
20. Smith G.A., Heuer A., Klein A., Vinh N.N., Dunnett S.B., Lane E.L. Amphetamine-induced dyskinesia in the transplanted hemi-Parkinsonian mouse. J Parkinson's Dis 2012, 2:107-113.
21. Thiele S.L., Warre R., Nash J.E. Development of a unilaterally-lesioned 6-OHDA mouse model of Parkinson's disease. J Vis Exp: JoVE 2012, 60:e3234. 10.3791/3234.
22. Bove J., Perier C. Neurotoxin-based models of Parkinson's disease. Neuroscience 2012, 211:51-76.
23. Jackson-Lewis V., Blesa J., Przedborski S. Animal models of Parkinson's disease. Parkinsonism Relat Disord 2012, 18(Suppl. 1):S183-S185.
24. Brundin P., Strecker R.E., Widner H., Clarke D.J., Nilsson O.G., Astedt B., et al. Human fetal dopamine neurons grafted in a rat model of Parkinson's disease: immunological aspects, spontaneous and drug-induced behaviour, and dopamine release. Exp Brain Res 1988, 70:192-208.
25. Mendez I., Baker K.A., Hong M. Simultaneous intrastriatal and intranigral grafting (double grafts) in the rat model of Parkinson's disease. Brain Res Brain Res Rev 2000, 32:328-339.
26. Mendez I., Sadi D., Hong M. Reconstruction of the nigrostriatal pathway by simultaneous intrastriatal and intranigral dopaminergic transplants. J Neurosci: Off J Soc Neurosci 1996, 16:7216-7227.
27. Nikkhah G., Duan W.M., Knappe U., Jodicke A., Bjorklund A. Restoration of complex sensorimotor behavior and skilled forelimb use by a modified nigral cell suspension transplantation approach in the rat Parkinson model. Neuroscience 1993, 56:33-43.
28. Piccini P., Lindvall O., Bjorklund A., Brundin P., Hagell P., Ceravolo R., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000, 48:689-695.
29. Cunningham L.A., Su C. Astrocyte delivery of glial cell line-derived neurotrophic factor in a mouse model of Parkinson's disease. Exp Neurol 2002, 174:230-242.
30. Espejo E.F., Gonzalez-Albo M.C., Moraes J.P., El Banoua F., Flores J.A., Caraballo I. Functional regeneration in a rat Parkinson's model after intrastriatal grafts of glial cell line-derived neurotrophic factor and transforming growth factor beta1-expressing extra-adrenal chromaffin cells of the Zuckerkandl's organ. J Neurosci: Off J Soc Neurosci 2001, 21:9888-9895.
31. Altar C.A., Boylan C.B., Jackson C., Hershenson S., Miller J., Wiegand S.J., et al. Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 1992, 89:11347-11351.
32. Bjorklund A., Rosenblad C., Winkler C., Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997, 4:186-200.
33. Thompson L.H., Grealish S., Kirik D., Bjorklund A. Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci 2009, 30:625-638.
34. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 247:574-577.
35. Mendez I., Dagher A., Hong M., Gaudet P., Weerasinghe S., McAlister V., et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: a pilot study. Report of three cases. J Neurosurg 2002, 96:589-596.
36. Ramaswamy S., Soderstrom K.E., Kordower J.H. Trophic factors therapy in Parkinson's disease. Prog Brain Res 2009, 175:201-216.
37. Truong L., Allbutt H., Kassiou M., Henderson J.M. Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behav Brain Res 2006, 169:1-9.
38. Zachrisson O., Zhao M., Andersson A., Dannaeus K., Haggblad J., Isacson R., et al. Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinson's Dis 2011, 1:49-63.
39. Nisancioglu M.H., Mahoney W.M., Kimmel D.D., Schwartz S.M., Betsholtz C., Genove G. Generation and characterization of rgs5 mutant mice. Mol Cell Biol 2008, 28:2324-2331.
40. Franklin K.B.J., Paxinos G. The mouse brain in stereotaxic coordinates 1997, Academic Press Limited.
41. Sarre S., Yuan H., Jonkers N., Van Hemelrijck A., Ebinger G., Michotte Y. In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem 2004, 90:29-39.
42. Blume S.R., Cass D.K., Tseng K.Y. Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism. Exp Neurol 2009, 219:208-211.
43. Steiner H., Kitai S.T. Unilateral striatal dopamine depletion: time-dependent effects on cortical function and behavioural correlates. Eur J Neurosci 2001, 14:1390-1404.
44. West M.J. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 1999, 22:51-61.
45. Smith G.A., Heuer A., Dunnett S.B., Lane E.L. Unilateral nigrostriatal 6-hydroxydopamine lesions in mice II: predicting l-DOPA-induced dyskinesia. Behav Brain Res 2012, 226:281-292.
46. Di Chiara G., Morelli M., Barone P., Pontieri F. Priming as a model of behavioural sensitization. Dev Pharmacol Ther 1992, 18:223-227.
47. Hudson J.L., van Horne C.G., Stromberg I., Brock S., Clayton J., Masserano J., et al. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res 1993, 626:167-174.
48. Kirik D., Rosenblad C., Bjorklund A. Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat. Exp Neurol 1998, 152:259-277.
49. Lee C.S., Sauer H., Bjorklund A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 1996, 72:641-653.